Trial Profile
Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Tyzivumab (Primary)
- Indications Zika virus infection
- Focus Adverse reactions
- Sponsors Tychan
- 08 Mar 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Mar 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 09 Mar 2020 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.